ArticleFrontiers in microbiology2025
Epidemiology and outcomes of Carbapenem-resistant Enterobacterales infection in high-risk patients in Saudi Arabia.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology, Molecular Characteristics, Treatment Patterns, and Outcomes of Carbapenem-Resistant Enterobacterales Infections in a Tertiary Hospital in Southern Saudi Arabia: A Retrospective Cohort Study.Journal of epidemiology and global health · 2026Article
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Clinical outcomes and treatment effectiveness in patients with carbapenem-resistant Enterobacterales infections: a multicenter retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Solid organ transplant (SOT) recipients, bone marrow transplant (BMT) recipients, and patients with hematological malignancies experience increased morbidity due to infections caused by multidrug-resistant, Carbapenem-resistant Enterobacterales (CRE). The current study aimed to further describe the epidemiology and outcomes associated with CRE infection in high-risk SOT and BMT recipients and in patients with hematological malignancies in Saudi Arabia. Methods: Patients aged 16 years and older admitted to a participating hospital between October 2018 and August 2024 who received an SOT or a BMT or were diagnosed with a hematological malignancy and had a confirmed CRE infection were included in this retrospective cohort study. A total of 155 eligible patients were included in the study population. The primary outcome of interest was all-cause mortality within 90 days of the date of the first CRE culture. Results: Among the 155 patients, 118 (76.1%) had received a solid organ transplant, while 37 (23.9%) had either a bone marrow transplant or a hematological malignancy. The BMT recipients and patients with hematological malignancies were 2.84 times more likely to die within 90 days of their first positive culture [adjusted odds ratio (AOR) = 2.84, 95% confidence interval (CI) = 1.01-8.01, Conclusion: The BMT recipients and patients with CRE infections harboring the blaOXA-48 gene were at greater risk for 90-day all-cause mortality in Saudi Arabia, confirming previous findings of high mortality rates associated with CRE infections in immunocompromised populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.